CHRISTIE BALLANTYNE to RNA, Small Interfering
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about RNA, Small Interfering.
Connection Strength
2.103
-
Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size and?Number?in?Hypertriglyceridemia. J Am Coll Cardiol. 2025 May 20; 85(19):1839-1854.
Score: 0.784
-
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):899-912.
Score: 0.742
-
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. 2024 09 12; 391(10):913-925.
Score: 0.186
-
Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of?siRNA Therapies for Prevention? J Am Coll Cardiol. 2023 12 12; 82(24):2262-2264.
Score: 0.180
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
Score: 0.128
-
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA. Atherosclerosis. 2025 04; 403:119114.
Score: 0.049
-
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies-a Clinical Perspective. Cardiovasc Drugs Ther. 2021 12; 35(6):1269-1279.
Score: 0.036